Urine test identifies more than nine in ten bladder cancers, clinical study finds
A new clinical study, led by the University of Birmingham and Nonacus Ltd., found that a noninvasive urine test called GALEAS™ Bladder accurately identified over 92% of bladder cancers in nearly 1,000 patients. The test showed 100% detection for muscle-invasive bladder cancers and a 99.3% probability of no cancer with a negative result.
Why it matters
This breakthrough offers a highly accurate and non-invasive method for early bladder cancer detection, potentially improving patient outcomes and reducing the need for more invasive diagnostic procedures.
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: CC0 Public Domain New research has found that more than 9 in 10 patients with bladder cancer were identified through a noninvasive urine test after urgent referral. The study, led by the University of Birmingham and Nonacus Ltd., involved 964 patients across seven NHS urology departments to examine the real-world significance of testing for bladder cancer using a commercially available urine test. GALEAS™ Bladder , which tests genomic information from a patient's urine for traces of bladder cancer, detected 71 of 77 cancers (92.2%) among the nearly 1,000 patients.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in